TABLE 1.
Demographic and clinical characteristics of patients with APS who received COVID‐19 vaccine
| N = 35 | |
|---|---|
| Age, y, median (min–max) | 43 (28–63) |
| Gender, female, number (%) | 33 (94.3) |
| Active smokers, number (%) | 2 (5.7) |
| Comorbidities, number (%) | |
| Hypertension | 6 (17.1) |
| Chronic kidney disease | 2 (5.7) |
| Sjögren's syndrome | 2 (5.7) |
| Diabetes mellitus | 0 |
| Coronary artery disease | 0 |
| Other | 4 (11.4) |
| Time from diagnosis, y, median (min–max) | 7.0 (1.0–27.0) |
| APS characteristics, n (%) | |
| Thrombotic APS | 22 (62.9) |
| Cerebrovascular event | 11 (52.4) |
| Deep vein thrombosis | 10 (47.7) |
| Pulmonary thromboembolism | 2 (9.6) |
| Obstetric APS | 21 (63.6) |
| Treatment agents, n (%) | |
| Hydroxychloroquine | 28 (82.4) |
| Acetylsalicylic acid | 16 (59.3) |
| Warfarin | 16 (48.5) |
| Corticosteroids | 15 (50) |
| Adherence to APS drugs during vaccination | 32 (97) |
Abbreviations: APS, antiphospholipid antibody syndrome.